Dr. Ansbert Gadicke led MPM's effort to build its Advisory and Investment Banking business from 1992 to 1996 and started its Asset Management business in 1996. MPM Capital is one of the world's largest dedicated investors in life sciences. With committed capital under active management in excess of $2.0 billion, MPM is uniquely structured to invest globally in healthcare innovation through its BioVentures family of venture capital funds.
Prior to founding MPM, Dr. Gadicke was employed by The Boston Consulting Group. Dr. Gadicke received an M.D. from J.W. Goethe University in Frankfurt. He subsequently held research positions in biochemistry and molecular biology at the Whitehead Institute at MIT, Harvard University and the German Cancer Research Center. He has published in leading scientific publications including Nature and Cell.
Dr. Gadicke is a Director of Cerimon Pharmaceuticals; Dragonfly Sciences; Elixir Pharmaceuticals; Radius Health and Solasia Pharma K.K., Tokyo. He previously served as a Director of Arriva Pharmaceuticals, BioMarin, Biovitrum, Coelacanth, Idenix, Kourion, MediGene, Omrix Biopharmaceuticals, Pharmasset, Inc.; PharmAthene, Transform, Xanodyne Pharmaceuticals, and ViaCell. He is a member of the Board of Fellows of Harvard Medical School.